Graham Capital Management, L.P. Bluebird Bio, Inc. Transaction History

Graham Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.85 - $1.26 $3,106 - $4,605	-3,655 Reduced 1.0%	361,826 $354,000
Q1 2024 May 15, 2024	SELL	$0.91 - $1.75 $81,760 - $157,232	-89,847 Reduced 19.73%	365,481 $467,000
Q4 2023 Feb 14, 2024	BUY	$1.32 - $4.83 $601,032 - $2.2 Million	455,328 New	455,328 $628,000
Q2 2023 Aug 14, 2023	BUY	$2.79 - $5.03 $265,195 - $478,111	95,052 New	95,052 $312,000
Q2 2022 Aug 15, 2022	BUY	$2.94 - $5.23 $2.3 Million - $4.09 Million	781,912 New	781,912 $3.24 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.